AVN-322

From Wikipedia, the free encyclopedia

AVN-322
Names
IUPAC name
5-(benzenesulfonyl)-N,11-dimethyl-2,3,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7-tetraen-4-amine;hydrochloride
Other names
List
  • 1194574-68-9
  • SB17475
  • 5-(Benzenesulfonyl)-N,11-dimethyl-2,3,7,11-tetraazatricyclo(7.4.0.0(2,6))trideca-1(9),3,5,7-tetraen-4-amine hydrochloride
  • starbld0039763
[1]
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • hydrochloride: InChI=1S/C17H19N5O2S.ClH/c1-18-16-15(25(23,24)13-6-4-3-5-7-13)17-19-10-12-11-21(2)9-8-14(12)22(17)20-16;/h3-7,10H,8-9,11H2,1-2H3,(H,18,20);1H
    Key: HLQZXWFRTGIZIJ-UHFFFAOYSA-N
  • free base: InChI=1S/C17H19N5O2S/c1-18-16-15(25(23,24)13-6-4-3-5-7-13)17-19-10-12-11-21(2)9-8-14(12)22(17)20-16/h3-7,10H,8-9,11H2,1-2H3,(H,18,20)
    Key: OSHBEPOEBKFEEK-UHFFFAOYSA-N
  • hydrochloride: CNC1=NN2C3=C(CN(CC3)C)C=NC2=C1S(=O)(=O)C4=CC=CC=C4.Cl
  • free base: CNC1=NN2C3=C(CN(CC3)C)C=NC2=C1S(=O)(=O)C4=CC=CC=C4
Properties
C17H20ClN5O2S
Molar mass 393.891 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

AVN-322 is a 5-hydroxytryptamine subtype 6 receptor antagonist manufactured by Avineuro Pharmaceuticals Inc. that could potentially be used to combat Alzheimer's disease and schizophrenia.[2][3] AVN-322 also reverses the negative effects of scopolamine and MK-80.[3]

The compound is a sister drug to AVN-101 and AVN-211, two similar compounds under trial for treating Alzheimer's.[3] Phase I trials for the drug were initiated in 2009 by Avineuro, and completed in the spring of 2010.[4][5] The trials showed that AVN-322 was tolerated in a range of doses without any adverse effects, and Avineuro released plans to commence Phase II trials later the same year.[5] The plan for further trials was discontinued in 2013.[6]

Related Articles

Wikiwand AI